Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ --

- Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule. All protocol-specified, interim masked analyses by the independent Data Monitoring Committee (DMC) have been completed. Recruitment is on track and the DMC, having found no safety concerns, has unanimously recommended proceeding without protocol modification.

Microplasmin's Phase III program is referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. This program involves two clinical trials, taking place in the United States (TG-MV-006 trial) and Europe and the United States (TG-MV-007 trial). The indication for both of the Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion.

Focal vitreomacular adhesion is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion which results in deterioration in the patient's vision. Moreover, vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also potentially associated with a much poorer prognosis in certain major eye indications, including diabetic retinopathy and Age-related Macular Degeneration (AMD).

Both of the Phase III studies are mult
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 The number of ... 45 people each day. Twenty-three percent of the workforce ... on Drug Use and Health, making opioid use a ... taking opioid painkillers at the correct dosage with a ... Today, the National Safety Council released ...
(Date:7/22/2014)... July 22, 2014  Based on its recent ... Frost & Sullivan recognizes Siemens Healthcare with the ... Healthcare,s FREEZEit solution, which employs Siemens, MAGNETOM Aera ... and motion-insensitive imaging. The solution,s sophistication and utility ... body MRI imaging in the U.S. market. ...
(Date:7/22/2014)... Pa. , July 22, 2014 Sanofi Pasteur, ... SNY ), announced today that the first lots of ... flu") season have been released by the U.S. Food and ... July 21, 2014, representing the first of at least 65 ... that will be delivered to U.S. health care providers and ...
Breaking Medicine Technology:5 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... are obese during pregnancy may be more likely to have ... "We found that, compared with children born from mothers ... during pregnancy had up to 20 to 30 percent higher ... assistant professor of pediatrics at Children,s Hospital of Pittsburgh. ...
(Date:7/22/2014)... E. Marc, Ph.D., director of research at the University ... named by the International Society of Eye Research (ISER) ... Foundation,s 2014 Paul Kayser International Award in Retina Research., ... who has made a significant contribution to the understanding ... presented this week at the ISER Biennial Meeting in ...
(Date:7/22/2014)... SIMpalm, a leading Mobile ... for Forte Payment System. Forte Mobile Payment app allows ... iPhone, iPod and iPad. The app was originally ... by SIMpalm. This update was for iOS 7.0 compatibility ... iOS 4.3 and is available to download on the ...
(Date:7/22/2014)... Washington, DC (PRWEB) July 22, 2014 Ticket ... vs. Inter Milan tickets at Fedex Field in Landover, MD. ... Sates to be a fan of international soccer. After the success ... in Brazil, soccer fever is alive and well. One way that ... hunger for the sport is with the 2014 Guinness International Champions ...
(Date:7/22/2014)... 22, 2014 (HealthDay News) -- One of the largest ... psychiatric disorder has uncovered 83 new sites on chromosomes ... findings, made by an international team of researchers, now ... to the disorder to 108. Although these ... a test to predict who will or will not ...
Breaking Medicine News(10 mins):Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... provides a simple solution to the learning challenges faced ... reading, writing, math, comprehension, verbalization, music and sports. ... on the use of 26 specific and integrative movements ... break through cognitive and sensory motor barriers that make ...
... available in French . , Montreal, March 23, ... immune system to combat the elusive virus responsible for cold ... advance online edition of Nature Immunology , a group ... with American colleagues, have identified a cellular process that seeks ...
... Existing Strong Position in Healthcare Investor and Media ... YORK, March 23 The Ruth Group (TRG), ... dedicated to healthcare and technology, announced today the ... healthcare marketing. The initiative leverages TRG,s strong ...
... HARRISBURG, Pa., March 23 State Health Secretary Everette ... of tuberculosis, or TB, and the importance of efforts ... 2008, we saw an increase in the number of ... resistant to medication, which makes the disease more difficult ...
... Ill., March 23 ACell, Inc. and ... signed an exclusive marketing and distribution agreement for ACell,s ... manufacture and Medline will market and distribute the products. ... bioscaffold derived from porcine tissue. When MatriStem is ...
... Blanco of San Diego, CA, will travel to ... 2009 to meet with congressional leaders and gain their ... toward a cure for epilepsy.Blanco, 7, is one of ... Kids Speak Up! , a national program coordinated ...
Cached Medicine News:Health News:Learning Empowered by Movement; Brain Gym Exercises Wake Up Brain and Body 2Health News:Herpes: Scientists find cellular process that fights virus 2Health News:The Ruth Group Launches Healthcare Marketing Communications Unit 2Health News:The Ruth Group Launches Healthcare Marketing Communications Unit 3Health News:Pennsylvania Sees Increase in Tuberculosis, Emphasizing Need for Awareness 2Health News:ACell and Medline Announce Exclusive Marketing and Distribution Agreement for MatriStem(TM) Proprietary Bioscaffold for Wound Care 2Health News:California Youth Shares Epilepsy Message on Capitol Hill 2
Puntenney curved forceps, curved, smooth 10 mm platforms....
Curved, very delicate, smooth jaws with platforms., ,Straight, very delicate, smooth jaws with platforms....
Gerl tying forceps, titanium, with 0.12 mm teeth....
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Medicine Products: